CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data

• The study showed a major response rate of 61.8%, meeting its primary endpoint.
• The company is preparing for potential regulatory submissions in the United States and Europe.
• Cellectar’s $140 million financing includes around $35 million in upfront payment, with $105 million tied to future milestones.

Cellectar Biosciences (CLRB) surged more than 27% on Tuesday, climbing to its highest level in more than six months, as investor optimism swelled following strong Phase 2 trial results for blood cancer treatment alongside a $140 million financing to advance the program’s next phase.

The company is preparing for potential regulatory submissions in the United States and Europe.

CLRB’s Phase 2 Trial Meets Primary Endpoint

Cellectar Biosciences reported strong results from its Phase 2b CLOVER WaM trial evaluating Iopofosine I 131 in patients with relapsed or refractory Waldenström macroglobulinemia (WM), a rare type of blood cancer.

With at least 12 months of follow-up, the study showed an overall response rate (ORR) of 83.6% and a major response rate (MRR) of 61.8%, meeting its primary goal. MRR is a stricter parameter for evaluating disease reduction. The trial also highlighted progression-free survival of 13.5 months.

The therapy also delivered strong results in patients who had previously been treated with BTK inhibitors, a type of targeted cancer therapy that blocks the growth of cancer cells. Safety remained manageable, with mostly mild side effects and low infection rates.

“We remain committed to providing Iopofosine I 131 to the thousands of patients who can benefit from treatment and plan to initiate our confirmatory study in the fourth quarter of this year,” said CEO James Caruso.

CLRB’s Pipeline To Get A Boost From $140 Million Financing

Separately, Cellectar Biosciences announced a financing deal that could raise up to $140 million to support its drug development efforts. The agreement includes about $35 million in upfront funding, with an additional $105 million tied to future milestones. The company will issue common stock through a registered offering, along with warrants and additional shares in a private placement.

The financing round was oversubscribed and backed by several healthcare funds, including Nantahala Capital Management, Balyasny Asset Management, Caligan Partners, and Janus Henderson Investors.

“This oversubscribed financing provides important validation of our strategy to pursue accelerated approval in the US and conditional marketing approval in Europe for Iopofosine, while supporting our plans to initiate a global confirmatory study in the fourth quarter of 2026,” Caruso added.

Retail Traders Expect CLRB Stock To Double In Value

Retail sentiment for CLRB on Stocktwits changed to ‘extremely bullish’ from ‘bullish’ a day earlier, while message volumes were ‘extremely high.’

One investor called the Phase 2 results “awesome” and expects the stock to climb to $7, nearly double its current value.

The stock has gained around 40% so far in 2026.

Read also: CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics?

For updates and corrections, email newsroom[at]stocktwits[dot]com.